Opioid antagonism enhances marijuana's effects in heavy marijuana smokers
- 19 May 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Psychopharmacology
- Vol. 211 (2), 141-148
- https://doi.org/10.1007/s00213-010-1875-y
Abstract
Studies in laboratory animals strongly suggest reciprocal modulation of the opioidergic and endocannabinoid systems, a relationship that has not been demonstrated in humans. This study sought to clarify this interaction by assessing how a range of naltrexone doses altered the subjective, cognitive, and cardiovascular effects of marijuana. Daily marijuana smokers (n = 29) participated in this within-subject, randomized, double-blind, placebo-controlled study. Naltrexone (0, 12, 25, 50, or 100 mg) was administered before active or inactive marijuana (3.27 or 0% THC) was smoked. Active marijuana increased subjective ratings of marijuana ‘Strength,’ ‘High,’ and positive subjective ratings of marijuana quality and drug effect including ‘Liking,’ ‘Good,’ and ‘Take Again’ compared to inactive marijuana. Naltrexone alone decreased ratings of ‘Liking,’ ‘Take Again,’ and ‘Stimulated’ compared with placebo, but increased ratings of drug ‘Strength,’ ‘High,’ ‘Good,’ ‘Liking,’ ‘Stimulated,’ and ‘Take Again’ when administered under active marijuana conditions. Active marijuana did not affect performance on cognitive tasks relative to inactive marijuana, whereas naltrexone decreased performance when administered alone or in combination with active marijuana. Active marijuana increased heart rate compared to inactive marijuana under placebo naltrexone conditions. Although naltrexone alone decreased heart rate, it further increased marijuana's cardiovascular effect. In heavy marijuana smokers opioid-receptor blockade enhanced the subjective and cardiovascular effects of marijuana, suggesting that endogenous opioids dampen cannabinoid effects in this population. These findings demonstrate that a broad range of clinically used doses of naltrexone potentially increases the abuse liability and cardiovascular risks of cannabinoids.Keywords
This publication has 30 references indexed in Scilit:
- Substitution profile of Δ9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Δ9-tetrahydrocannabinolPsychopharmacology, 2008
- Advances in the field of cannabinoid–opioid cross‐talkAddiction Biology, 2008
- Interactions between Δ9-tetrahydrocannabinol and μ opioid receptor agonists in rhesus monkeys: discrimination and antinociceptionPsychopharmacology, 2008
- Blockade of THC-Seeking Behavior and Relapse in Monkeys by the Cannabinoid CB1-Receptor Antagonist RimonabantNeuropsychopharmacology, 2008
- Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis usersPsychopharmacology, 2007
- Opioid Antagonism of Cannabinoid Effects: Differences between Marijuana Smokers and Nonmarijuana SmokersNeuropsychopharmacology, 2006
- Motivational Effects of Cannabinoids and Opioids on Food Reinforcement Depend on Simultaneous Activation of Cannabinoid and Opioid SystemsNeuropsychopharmacology, 2005
- CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid‐seeking behaviour in the ratBritish Journal of Pharmacology, 2004
- β‐Endorphin elevations in the ventral tegmental area regulate the discriminative effects of Δ‐9‐tetrahydrocannabinolEuropean Journal of Neuroscience, 2004
- Naltrexone does not block the subjective effects of oral Δ9-tetrahydrocannabinol in humansDrug and Alcohol Dependence, 2000